Market LIVE
Published markets; coverage varies by country
Product profile · United States

ATONCY

 ·  Patent Litigation & Settlement History ↓

IngredientATOMOXETINE HYDROCHLORIDE
Application typeNDA
Application220320
Product001
Dosage formSOLUTION
RouteORAL
StrengthEQ 4MG BASE/ML
Approval date2026-03-20
Marketing statusPrescription
Status event—
ApplicantMAP77
Product source

Current GenericRadar decision

Year2017
SelectionCANDIDATE
ReviewFINAL
Anchor typeDS_EQUIVALENT_PATENT
Anchor date2017-05-26
Patent anchor2017-05-26
Exclusivity anchor2007-11-26
Protection date2017-05-26
First Final ANDA—
Status event—

Candidate based on the adopted canonical anchor; no later applicable right was adopted from the reviewed sources.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US56585902017-05-26HISTORICAL_REFERENCE_NOT_EXACT_OB U-494NYU
Independent claim 1 treats ADHD with an effective amount of tomoxetine without age, release-form or excipient restrictions. Adopted as a full-scope use anchor. Historical FDA dates: base 2016-11-26, PED 2017-05-26.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2002-11-262007-11-26Historical protection covering the active ingredient. This is a reference period, not a new grant to the later NDA.YY2007-11-26—Source

2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (3)
TypeDateRoleBasisSource
PATENT2017-05-26CANONICAL_ANCHORIndependent claim 1 treats ADHD with an effective amount of tomoxetine without age, release-form or excipient restrictions. Adopted as a full-scope use anchor. Historical FDA dates: base 2016-11-26, PED 2017-05-26.Source
REGULATORY_EXCLUSIVITY2007-11-26CANONICAL_ANCHORHistorical protection covering the active ingredient. This is a reference period, not a new grant to the later NDA.Source
REGULATORY_STATUS2017-05-26CANONICAL_DECISIONCandidate based on the adopted canonical anchor; no later applicable right was adopted from the reviewed sources.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.